BOULDER, Colo., Oct. 29, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2015 and hold a conference call to discuss those results on Tuesday, November 4, 2014. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.
Date: Tuesday, November 4, 2014
Time: 9:00 a.m. Eastern Time
Toll-Free: (800) 708-4540
Toll: (847) 619-6397
Pass Code: 38177000
Webcast, including Replay and Conference Call Slides:
http://www.media-server.com/m/acs/835a9ca60ab7df8747dc3aa3ad1d878b
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Phase 3 studies are in progress, or are planned to begin this year. These programs include the wholly-owned hematology drug, filanesib (ARRY-520) for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and binimetinib (MEK162 / Novartis). For more information on Array, please go to www.arraybiopharma.com.
CONTACT: Tricia Haugeto Array BioPharma Inc. (303) 386-1193 thaugeto@arraybiopharma.com
SOURCE Array BioPharma